Vaccination against HPV virus (Human Pappiloma Virus) and indirectly against cervical cancer. Here an overview of the advantages and disadvantages and doubts about the vaccination program.
6 apriil 2010:
Complementary to below article about the doubts surrounding the vaccination of girls and young women against HPV virus and cervical cancer , we have therefore indirectly against a piece of copied from a Canadian Medical Association or the Canadian writing KNMG. Which they rehearse on why they believe that women and girls need to be vaccinated but not yet. Full texts with charts and study evidence etc. read here : http://www.cmaj.ca/cgi/content/full/177/5/484
The main copied:
..... A careful review of the literature, including that submitted by the manufacturer with its application for approval of Gardasil, reveals a sufficient number of unanswered questions to lead us to conclude that a universal immunization program aimed at girls and women in Canada is, at this time, premature and could possibly have unintended negative consequences for individuals and for society as a whole.
• There is no epidemic or cervical cancer in Canada to warrant the sense of urgency for a vaccination program initiated by the federal finance Minister's announcement. .......... Both the incidence and mortality of cervical cancer have been declining in Canada, as in other resource-rich countries, although recently at a somewhat slower rate than has been observed in previous decades ... ....
• Invasive cervical cancer typically follows a slowly progressive course that can be halted at one or various internships. The dramatic decrease in deaths from cervical cancer in Canada, even before the development of any vaccine, represents a public health success (Figure 1). ......... Consequently, deaths from cervical cancer — relatively rare in Canada but always unfortunate and not distributed evenly among women — must be considered as a failure in the adequate support of both the primary care and reproductive health services that would guarantee healthy living conditions for all women. Improvements here, as well as steps to ensure that all women receive appropriate Pap testing and follow-up, are needed.
Most HPV infections are spontaneously cleared •. Recent research using available molecular detection technologies has suggested that clearance occurs within 1 year for about 70% of infected women, and within 2 years for 90%.7 Thus, HPV infection and cervical cancer must not be conflated: cervical cancer will not develop in most women who are infected with even a high-risk strain or HPV ... ...
• .....
• Information about the efficacy of Gardasil remains uncertain. Its real-world effectiveness is even less clear. Todate, only a handful of randomized controlled trials of sufficient quality to qualify for systematic review have been reported. 9 Interestingly, each of the reported HPV vaccine trials, whether or Cervarix Gardasil or its potential competitor, was funded in whole or in part by the manufacturer vaccine's.Although Rambout and colleagues, 9 in their systematic review (see page 469), find that overall the vaccine is highly efficacious in the short term, particularly when all clinical outcomes are pooled, they also note that some methodologic weaknesses in the trial reports, combined with the limits in currently available data, continue to leave many information gaps. This situation is not unusual at this juncture in the development of new pharmaceutical products; however, it does caution against making overly optimistic descriptions of benefits and downplaying potential risks.
• We would add a number of questions to those raised by Rambout and colleagues. Specifically, what is the length of immunologic protection the vaccine confers against HPV types 16 and 18? Boosters Will be needed to maintain this limited coverage, and if so, when? Other questions with regard to effectiveness centre on concerns about the possibility of short-term immunity altering the natural history of viral infection, as seems to be the situation with chicken pox: protection has been or shorter duration than expected, and viral infections in older people have been more severe than those in 10 children.
• Furthermore, we lack data on the effectiveness of the HPV vaccine when co administered with other immunizations, as may occur in real practice. As well, will such factors as a person's nourishment, smoking status and general health (e.g., comorbidities) influence the safety or usefulness of the HPV vaccine? Perhaps more importantly, might misunderstandings about what the vaccine does and does not do lead to reductions in safer sex practices and Pap screening rates? ......
• Relatively few girls (about 1200 aged 9 – 15 years) were enrolled in the clinical trials of Gardasil, the youngest of whom were followed for only 18 months ... ....
• Gardasil is the most expensive childhood vaccine proposed for mass use; ....... The lack of effectiveness data makes it difficult to estimate what reduction in repeat testing or smears, colposcopy can be anticipated to counter some of the vaccination costs and precludes determining whether vaccination will have any "added value." ... ....
Below the Dutch still some things that seem important to the vaccination programme against HPV virus but all previously published.
15 september 2009:
Vaccination against HPV virus (Human Pappiloma Virus) and indirectly against cervical cancer costs human lives and caused 6.7% serious adverse reactions including a number of deaths, according to new studies. Researchers set the question after this study or the benefits of vaccination outweigh the disadvantages. We have already published studies that demonstrate that bv. green tea regularly drinking or use of a medicinal mushrooms (PSK) fabric from is effective in combating and preventing an infection with the HPV virus
A summary of articles about the latest findings published on CBS News:
At first glance, the study report, published on 19 August in The Journal of The American Medical Association (JAMA) reasonably mild about the safety of the vaccination with Gardasil, the vaccine against HPV virus-human papillomavirus and in accordance with the results from the studies that the safety requirements of the FDA had to demonstrate. June 2006 gave the FDA (Food and Drug Administration) on the basis of security studies in May to put permission to Gardasil as fight of the HPV virus and thus indirectly against the emergence of cervical cancer for girls and young women aged 9 to 26 years. The four types of HPV-virus: types 16 and 18 can cause cervical cancer and the types 6 and 11 are the most common forms that play a role in the emergence of genital warts.
Now researchers and doctors agree the study report from JAMA accurately viewed and shows that there is a number of additional disturbing facts are to sign up.
As it turns out the vaccine to cause a number of negative side effects. In previous studies, these were listed as rare where but from a new study shows that cases of epileptic seizures and thrombosis-blood clots in the blood-more frequent than previously reported and especially much more serious in nature. Between the 12.424 reports of side effects about the HPV vaccine, were 772 (6.2%) notifications of serious and 32 were done notifications of death to one of the side effects. It is not clear whether all 32 deaths are directly attributable to the administration of the vaccination with Gardasil, but a large number of them seem to be related to the vaccination.
Other problems caused by the vaccine are local reactions such as rash, nausea, dizziness, headache, and even a case of Guillain-Barre syndrome (a disorder of the peripheral nervous system that sometimes caused a full paralysis) and Anaphylaxis (allergic reaction that can lead to sudden death). CBS News reported last week a case of a teenage girl, daughter of a doctor who is a chronic autoimmune disease, myofasciitis, had gotten after her first dose of Gardasil.
In an editorial guidance of the JAMA study, Charlotte Haug, m.d., Ph.d., m.SC., (Norwegian Medical Association) her concern about the aggressive way in which the Gardasil vaccine is promoted: "Or a risk is worth depends not only on the absolute risk, but also of the relationship between the potential risk and the possible advantage. If the potential benefits are large, most people would be willing to accept the risks. But thenet advantage of the HPV vaccine for a woman is uncertain. Even if a woman is a woman most likely chronically infected with HPV will not develop cancer if they are screened regularly ... "
Even Dr. Diana Harper, spokeswoman medical caregiver of the phase I and II studies with Gardasil and paid fellow works of Merck also displays criticisms. It argues inter alia that there was no evidence that vaccination with Gardasil is employed longer than 5 years. Which would mean that a girl on her on her 15th al no longer is vaccinated 10 is sure of protection. Dr. Harper notes further on: "The number of women who die from cervical cancer in the u.s. every year is small but real. It is small because of the success of the Pap screening program. " In other words there are not so many people die on cervix cancer but this is mainly because it is screensprogramma with a smear successful and preventive.
Dr. Harper also says that Gardasil for women in developing countries where no good screening programme consists perhaps can work but in the USA and Europe well perhaps to a too big confidence in the operation of the vaccine may cause unsafe sex and no annual will smear more often women will do.: "The future expectations women hold because they have received free doses of Gardasil purchased by philanthropic foundations, by public health agencies or covered by insurance is the true threat to cervical cancer in the future. Should women stop Pap screening after vaccination, the cervical cancer rate will actually increase per year. Should women believe this is preventive for all cancers-something never stated, but often inferred by many in the population--a reduction in all health care will compound our current health crisis. Gardasil Should not be effective for more than 15 years, the most costly public health experiment in cancer control will have failed miserably. "
Dr. Harper says the risk-benefit analysis for Gardasil in other countries may shape up differently than what she believes is true in the US. "Of course, in developing countries where there is no safety Pap screening for women repeatedly over their lifetime 's, the risks of serious adverse events may be acceptable as the incidence rate of cervical cancer is five to 12 times higher than in the u.s., dwarfing the risk of death reported after Gardasil."
